Medacta to Keep Growing But Faces Normalization — Market Talk
Medacta should continue to book above-market growth rates but market expectations currently underestimate growth normalization and the investment required to sustain expansion, Deutsche Bank says in a research note. "While Medacta's competitive advantages remain intact, sustaining its historical gr…